Assessment of novel cardiovascular biomarkers in chronic obstructive pulmonary disease
Kumiko Hiramatsu1,2, Takashi Motegi3, Keiko Morii3
1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. kumiko@rcc-icr.com.
Insights
Galectin-3 (Gal-3) levels correlate with cardiovascular biomarkers like NT-proBNP and exercise capacity in COPD patients. This suggests Gal-3 may help identify cardiovascular comorbidity in those with chronic obstructive pulmonary disease (COPD) and pre-COPD.
Area of Science:
- Pulmonary Medicine
- Cardiology
- Biomarker Research
Background:
- Cardiovascular disease frequently co-occurs with chronic obstructive pulmonary disease (COPD) and pre-COPD, significantly increasing morbidity and mortality.
- Investigating biomarkers for cardiovascular comorbidity in COPD patients is crucial for improving patient outcomes.
Purpose of the Study:
- To determine if Galectin-3 (Gal-3) levels correlate with cardiovascular biomarkers and cardiopulmonary function in COPD and pre-COPD patients.
- To assess the potential of Gal-3 as a marker for cardiovascular comorbidity in this population.
Main Methods:
- Recruited community-dwelling adults with and without COPD.
- Measured biomarkers including Galectin-3 (Gal-3), high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal pro-brain natriuretic peptide (NT-proBNP).
- Conducted pulmonary function tests, chest CT, echocardiograms, and a 6-minute walking test to assess cardiopulmonary function.
Main Results:
- Gal-3 levels showed a significant correlation with NT-proBNP and a negative correlation with maximal pulse rate during the 6-minute walking test.
- No significant correlation was found between Gal-3 and hs-cTnT.
- hs-cTnT levels correlated significantly with age, FEV1%, E/A ratio, walking distance, deceleration time, right ventricular systolic pressure, and hs-CRP.
Conclusions:
- Gal-3 levels correlate with NT-proBNP and maximal pulse rate in COPD and pre-COPD patients.
- These findings support the investigation of Gal-3 as a potential biomarker for cardiovascular comorbidity in COPD populations.
Background:
Cardiovascular disease is a common comorbidity in chronic obstructive pulmonary disease (COPD) and pre-COPD patients, contributing significantly to morbidity and mortality. We aimed to investigate whether Galectin-3 (Gal-3) levels correlate with cardiovascular biomarkers and cardiopulmonary function in COPD and pre-COPD patients to assess its potential role as a marker for cardiovascular comorbidity.
Methods:
Community-dwelling adults with and without COPD were recruited. Biomarkers including Gal-3, high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured. Subjects underwent pulmonary function tests, chest CT, echocardiograms, and a 6-minute walking test. The relationships between biomarkers and cardiopulmonary function were examined.
Results:
Among 120 subjects (97 COPD, 23 pre-COPD), the mean age was 70.2 years, and the mean predicted forced expiratory volume in 1 s (FEV1%) was 68.5%. Gal-3 levels averaged 1733.7 pg/mL. Gal-3 significantly correlated with NT-proBNP (ρ = 0.229, p = 0.012) and negatively with maximal pulse rate during the 6-minute walking test (ρ=-0.185, p = 0.043). No significant correlation was found between Gal-3 and hs-cTnT levels. However, hs-cTnT levels showed significant negative correlations with age (ρ=-0.526, p < 0.001), FEV1% (ρ=-0.373, p < 0.001), E/A ratio (ρ=-0.390, p < 0.001), and walking distance (ρ=-0.444, p < 0.001), and positive correlations with deceleration time (ρ = 0.299, p = 0.001), right ventricular systolic pressure (ρ = 0.197, p = 0.037), and high-sensitivity C-reactive protein (ρ = 0.212, p = 0.020).
Conclusions:
Gal-3 levels show correlations with NT-proBNP and maximal pulse rate, supporting its investigation as a potential marker for cardiovascular comorbidity in COPD and pre-COPD populations.
More Related Videos
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation